First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Alfredo Addeo MD, Giulio Metro MD

Abstract

In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib as the first approved targeted drug, to the meaningful improvement in terms of clinical benefit that alectinib, a second generation ALK-inhibitor, has recently provided over crizotinib. Finally, we address major trends of clinical research in this setting, and whether this might translate into further clinical improvement in the near future.

Article Details

Article Type

Editorial

DOI

10.7573/dic.212537

Publication Dates

Accepted: ; Published: .

Citation

Addeo A, Metro G. First-line alectinib for ALK-positive lung cancer: is there room for further improvement? Drugs in Context 2018; 7: 212537. DOI: 10.7573/dic.212537

Article Views

Monthly article views (last 9 months)

Drugs in Context PubMed Central
Source HTML views PDF downloads Totals
Drugs in Context since September 15, 2025 119 3 122
PubMed Central since February 1, 2025 0 0 0
Totals 119 3 119
Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.